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Background: Metal organic frameworks (MOFs) have attracted more attention in the last 
decade because of a suitable pore size, large surface area, and high pore volume. Developing 
biocompatible MOFs such as the MIL family as a drug delivery system is possible.
Purpose: Flurbiprofen (FBP), a nonsteroidal anti-inflammatory agent, is practically insoluble in 
aqueous solution, and, therefore, needs suitable drug delivery systems. Different biocompatible 
MOFs such as Ca-MOF and Fe-MILs (53, 100, and 101) were synthesized and employed for 
FBP delivery.
Patients and methods: A sample of 50 mg of each MOF was mixed and stirred for 24 h with 
10 mL of 5 mg FBP in acetonitrile (40%) in a sealed container. The supernatant of the mixture 
after centrifuging was analyzed by high-performance liquid chromatography to determine the 
loaded quantity of FBP on the MOF. The overnight-dried solid material after centrifuging 
the mixture was analyzed for loading percent using X-ray diffraction, Fourier-transform 
infrared spectroscopy, scanning electron microscopy, nuclear magnetic resonance, and FBP 
release profile.
Results: The loading values of FBP were achieved at 10.0%±1%, 20%±0.8%, 37%±2.3%, and 
46%±3.1% on Ca-MOF, Fe-MIL-53, Fe-MIL-101, and Fe-MIL-100, respectively. The FBP 
release profiles were investigated in a phosphate buffer solution at pH 7.4. The total release of 
the FBP after 2 days was obtained at 72.9, 75.2, 78.3, and 90.3% for Ca-MOF, Fe-MIL-100, 
Fe-MIL-53, and Fe-MIL-101, respectively.
Conclusion: The MOFs are shown to be a promising drug delivery option for FBP with a 
significant loading percent and relatively prolonged drug release.
Keywords: porous MOF, FBP, drug loading, drug release
Introduction
Over the last 20 years, a number of different nanoparticle-based strategies have 
been developed to improve the efficacy of conventional drug delivery.1,2 Porous and 
tunable hybrid materials, metal organic frameworks (MOFs), are promising candi-
dates as potential drug carriers, because of their remarkably large surface areas and 
excessively high porosities.3,4 The adjustment of the framework’s functional groups 
and pore size make it advantageous over rigid nanoparticle carriers in biomedical 
applications.5 Although several types of organic carriers at a nanoscale level such as 
micelles, liposomes, and dendrimers6–9 have been employed for drug delivery, the drug 
release is difficult to control with an absence of tunable porosity.10 In contrast, MOF 
nanoparticles have a high loading capacity and controlled drug release properties.2
Moreover, the toxicity and biocompatibility of metals and organic linkers used in 
MOFs have been evaluated.11 Biocompatible metals including Ca, Cu, Mn, Mg, Zn, and 
Fe may accumulate in the body during the drug release process. However, Fe-MIL-88A 
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is approved as an oral iron supplement.11 Toxicological 
studies on Fe-MIL-88 and Fe-MIL-101 have indicated an 
optimistic view on the toxicity of MOFs.12,13 Organic linkers 
are either exogenous or endogenous compounds. Exogenous 
organic linkers are produced from polycarboxylates, imida-
zolates, pyridyl, and amines.14 Several endogenous organic 
linkers are ingredients of the body composition, and have 
been used for synthesis of biocompatible amino acid MOFs 
and nucleobase MOFs.15
Currently, the most studied MOFs for drug delivery 
have used Fe metal with bio-organic linkers, such as MILs 
(53, 88, 100, and 101).11,16,17 Bernini et al studied a potential 
carrier of ibuprofen by comparing validated simulation data 
for ibuprofen adsorption and release in MIL-53, MIL-100, 
and MIL-101 with interesting CDMOF-1, MOF-74, and 
BioMOF-100.18 Porous iron carboxylate MOFs have been 
successfully used for encapsulation of a challenging antitu-
mor molecule performing unprecedented loadings exceeding 
25 wt%, which may allow the administration of high doses 
of drugs using low amounts of MOFs.19,20 Bio-application 
studies of a calcium inorganic linker-based MOF are few, 
however; Sumida et al explored the potential use of calcium 
carbonate as a precursor to MOF materials to form highly 
crystalline products.21
Flurbiprofen (FBP) (Figure 1) is a hydrophobic and 
potent acidic nonsteroidal anti-inflammatory drug, which 
has a molecular weight of 244.3, pKa of 4.6, and log P-value 
of 4.16. It is practically water insoluble.22 To reduce the 
potential side effects of FBP, numerous delivery systems 
have been designed, such as transdermals, microspheres, 
microsponges, and niosomes.23 To maintain a prolonged 
therapeutic activity, the rate of FBP release in different sur-
factants is low at 10%–60%.24 This study aims to develop a 
substantially improved loading percent and release profile 


































 100%), dimethylformamide (DMF, 




O, .95%) were purchased from 
Sigma,  Sydney, NSW, Australia and used without further 









 85%) were supplied by Fisher Chemical, Belgium.
synthesis of MOFs
Solvothermal and hydrothermal synthesis procedure was used 
to prepare the MOFs by Teflon-lined steel autoclave at mild 
temperature (Teflon-line autoclave [4744 Acid Digestion 
Bomb] with a capacity of 125 mL supplied by John Morris 
Scientific Pty Ltd, Australia).
Ca-MOF was synthesized solvothermally by using a mul-
tisolvent solution in a Teflon-lined steel autoclave. A mixture 
of calcium nitrate tetrahydrate (18 mmol), terephthalic acid 
(9 mmol), acetic acid (407 mmol), ethanol 48.6 mL, and 
distilled water (13.5 mL) was incubated at 165°C for 1 day. 
Then it was immersed in 100 mL of acetonitrile (ACN) for 
4 days until a white powder precipitated. The white powder 
was filtered by vacuum filtration and dried at 100°C and, 
finally, it was dried at 170°C overnight.
Fe-MIL-53 was synthesized specifically by mixing 




O (10 mmol) in 
50 mL of DMF at 150°C for 65 h. The product was centri-
fuged and then washed in water many times. The obtained 
solid was filtered, washed with DMF, and stirred successively 
in 200 mL of methanol for 10 h and in 200 mL of water for 
15 h.25 After drying in an oven at 70°C, a yellowish-brown 
powder was recovered.
Fe-MIL-101 was prepared by mixing terephthalic acid 




O (5 mmol) in 30 mL of DMF. 
Then the mixture was transferred to an autoclave of 45 mL 
and heated in an oven at 110°C for 20 h.26 The product was 
immersed in hot ethanol twice during 3 h. After drying in an 
oven at 70°C, an orange-brownish powder was recovered.







BTC (trimesic acid) in 36 mL of distilled 
water inside an autoclave of 125 mL and heated in an oven at 
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MOF as flurbiprofen delivery system
was centrifuged and the solid was washed successively 
in hot water (350 mL, 70°C and 3 h) and in hot ethanol 
(250 mL, 65°C and 3 h). The obtained orange-brownish 
powder was dried at 90°C overnight.
characterization of MOFs
X-ray powder diffraction (XRPD) patterns were obtained 
using a D8 Advance (Bruker AXS, Germany), with a copper 
Kα radiation source (40 kV and 40 mA) with a Lynx Eye 
detector. The 2-theta scan range was of 5–40 degrees. 
Fourier-transform infrared (FTIR) spectra of all the MOFs 
and loaded MOFs were measured using a PerkinElmer FTIR 
spectrometer in the range of 650–3,800 cm−1. The surface 
morphology imaging of the MOFs was achieved by using 
Zeiss Neon 40 EsB field-emission scanning electron micros-
copy (SEM) with SmartSEM software. Nuclear magnetic 
resonance (NMR) spectroscopy provides a better under-
standing of the loading behavior in the drug delivery system. 
NMR spectra were acquired on a Bruker Avance Ultrashield 
400 MHz spectrometer and the NMR spectra were referenced 
to their solvents: deuterium oxide (D
2
O, 1H, δ4.79 ppm). 
Also, textural properties of MOFs were characterized by 
N
2
 adsorption–desorption isotherms, which were obtained 
at −196°C by Micromeritics, Tristar instrument, to determine 
the specific surface area, pore size, and volume.
incorporation of FBP with MOFs
The FBP calibration assay was analyzed by high-performance 
liquid chromatography (HPLC) (Shimadzu 20 AC) at a range 
of FBP concentrations (10, 20, 30, 40, 50, and 60 µg/mL in 
methanol [90%]) and the mobile phase was 0.1 M phosphate 
buffer solution (PBS) pH 6.8 and ACN (40%). A sample of 
50 mg of FBP was dissolved in 10 mL of ACN (40%) to 
make an FBP solution of 5 mg/mL. An aliquot of 100 µL 
was withdrawn and diluted to 10 mL with ACN (40%) and 
analyzed by HPLC to determine the amount of FBP before 
loading. The MOFs were dried at 120°C for 6 h before 
loading in the FBP solution. A dried sample of 50 mg of 
each MOF was separately weighed and mixed with the FBP 
solution in 20 mL glass containers. After sealing the con-
tainer tightly, the mixture was stirred (at 100 rpm) for 24 h 
at room temperature by a magnetic stirrer. The supernatant 
was collected after centrifugation (4,000 rpm, 15 min). The 
material of MOF with loaded FBP (FBP@MOFs) in the 
bottom of centrifugal tube was immediately washed with 
10 mL of 40% ACN and centrifuged to remove FBP adsorbed 
on the outer surface of MOFs. Then the FBP@MOF material 
was dried overnight at 60°C in an oven. An aliquot of 100 µL 
was withdrawn from the supernatant, diluted to 10 mL with 
ACN (40%), and analyzed by HPLC to determine the remain-
ing amount of FBP in the solution after loading. The loading 
amount of FBP can be calculated by subtracting the amount 
of FBP in the supernatant solution from the amount of FBP 
before loading. The loading percentage can be calculated by 
employing the following equation:
 
Drug loading %
Weight of  drug in the MOF




A predetermined quantity of FBP@MOF accurately weighed 
was submerged into 10 mL of preheated dissolution medium 
(50 mmol PBS) at pH 7.4 confined in sealed 20 mL capacity 
glass vials maintained at 37°C±1°C with a constant stirring 
at a rate of around 75 rpm. At predetermined time intervals 
(0.25, 0.5, 1, 2, 3, 5, 8, 12, 24, and 48 h), an aliquot of 50 µL 
was withdrawn and replaced with the same volume of fresh 
dissolution medium. The aliquots were diluted 100 times with 
the same buffer solution and filtered by 0.2 µm syringe filter 
and analyzed using HPLC. A correction of the FBP amount 
in dissolution medium extracted was calculated regarding the 
FBP lost in each aliquot. The released percent of FBP was 
calculated according to the following equation:
 
% Release
Actual FBP released at any time (mg)
Amount of  FB
=







XRPD data indicated that the crystallinity of FBP@MOFs 
was significantly changed in respect to the unloaded MOFs 
(Figure 2). The level and intensity of the peaks were signifi-
cantly reduced. The peak positions in the XRPD patterns 
were similar for the FBP@MOF and the unloaded MOF. 
This indicates that the MOF structures were stable after FBP 
loading within all MOFs.
FTIR spectra of pure MOFs and FBP@MOFs are shown 
in Figure 3. The peak at 1,694 was assigned to the carboxyl 
group in FBP. The peak at 1,690 cm−1 in Fe-MIL-53, Fe-MIL-
100, and Fe-MIL-101 and FBP-loaded samples was assigned 
to C=O stretching. The peak at 1,621 cm−1 in Ca-MOF and 
FBP@Ca-MOF was also assigned to C=O stretching. The 
shift in carboxyl group from 1,694 to 1,621 cm−1 is because of 
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preparation of the Ca-MOF; the larger shift of the carboxyl 
group is due to the stronger acidity,27 while one acid type was 
used with the other MOFs. The FTIR spectrum shows the 
stretching of the carboxyl group of all loaded MOFs indicat-
ing the presence of FBP molecules in all FBP@MOFs.
SEM images of MOFs and FBP-loaded MOFs, as shown 
in Figure 4, are represented by A, A, B, B, C, C, D, and D, 
which are Ca-MOF, FBP@Ca-MOF, Fe-MIL-53, FBP@
Fe-MIL-53, Fe-MIL-101, FBP@Fe-MIL-101, Fe-MIL-100, 
and FBP@Fe-MIL-100, respectively. Figure 4 shows the 
nature of microcrystallinity and relatively similar shape and 
size of each raw MOF and the corresponding loaded one. 
However, the nature of the surface morphology of FBP@
MOFs was changed. Ca-MOF and the corresponding loaded 
one show that they are rod-shaped, while Fe-MIL-53 and 
the corresponding loaded one show a platelet shape with an 
average length of crystals in the micron range. Fe-MIL-100 
and the corresponding loaded one have a triangular base 
pyramid shape, while Fe-MIL-101 and the corresponding 
loaded one have a needle shape. The SEM images of FBP@
MOFs indicate an inflated morphology as compared to the 
bare MOF, suggesting a filling of the drug in the porous MOF. 
This result indicates loading of FBP within the MOFs.
NMR spectroscopy was employed for investigation of 
FBP loading within all MOFs. The presence of a signal at 
1.25 ppm of pure FBP and its loaded MOFs (Figure S1) was 
an indication of resonance spectroscopy of methyl group in 
the FBP structure (Figure 1). This result indicates the pres-
ence of FBP molecules within all MOFs.
N
2
 adsorption–desorption isotherms were obtained and 
analyzed to determine the surface area, pore size, and pore 
volume of each MOF. Based on the N
2
 adsorption isotherms, 
the Brunauer–Emmett–Teller (BET) surface area of all MOFs 
is reported in Table 1. The pore volumes obtained from the 
isotherm at P/Po =1 (Figure S2) and the average pore sizes 
of all MOFs are also listed in Table 1. Figure S2 shows 
the degree of hysteresis and mesopore content in Ca-MOF, 
Fe-MIL-53, Fe-MIL-100, and Fe-MIL-101, respectively. 
Figure 2 X-ray powder diffraction of (A) ca-MOF and FBP@ca-MOF, (B) Fe-Mil-53 and FBP@Fe-Mil-53, (C) Fe-Mil-101 and FBP@Fe-Mil-101, (D) Fe-Mil-100 and 
FBP@Fe-Mil-100.
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MOF as flurbiprofen delivery system
The sharp increase in N
2
 adsorption at a pressure close to 1 
demonstrates the availability of macropore in their structure 
as shown clearly with a wide range in the isotherms of Ca-
MOF, Fe-MIL-53, and Fe-MIL-101, which was very limited 
in the isotherm of Fe-MIL-100. Also, a wide hysteresis via a 
long range of relative pressure in Ca-MOF followed by Fe-
MIL-53 and Fe-MIL-101 represents the mesopore content 
due to ink-bottle pore effect.28 However, the sharp increase 
in N
2
 adsorption at a low relative pressure represents the 
micropore, which is supported by overlapping N
2
 adsorption–
Figure 3 Fourier-transform infrared spectra of (A) Ca-MOF (red) and FBP@Ca-MOF (blue), (B) Fe-MIL-100 (red) and FBP@Fe-MIL-100 (blue), (C) Fe-Mil-101 (red) and 
FBP@Fe-MIL-101 (blue) and (D) Fe-MIL-53 (red) and FBP@Fe-MIL-53 (blue).
Note: FBP spectrum (black).
Abbreviations: FBP, flurbiprofen; MOF, metal organic framework.
Figure 4 scanning electron microscopy images of (A) ca-MOF, (Ā) FBP@ca-MOF, (B) Fe-Mil-53, (B̄) FBP@Fe-Mil-53, (C) Fe-Mil-101, (C̄) FP@Fe-Mil-101, (D) Fe-Mil-
100, and (D̄) FBP@Fe-Mil-100.






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




al haydar et al
desorption isotherms as shown obviously in the isotherms of 
Fe-MIL-100 and Fe-MIL-101.
Drug loadings
The loading percentage values of FBP on the MOFs 
were around 46%, 37%, 20%, and 10% for Fe-MIL-100, 
Fe-MIL-101, Fe-MIL-53, and Ca-MOF, respectively, as 
shown in Table 1. The highest loading percent was on 
Fe-MIL-100 followed by Fe-MIL-101, which is correlated 
to the MOF characteristics of high surface area and pore 
volume. The surface areas of Fe-MIL-53 and Ca-MOF were 
26.20 and 34.72 m2/g, respectively, while the pore sizes 
were 12.3 and 12.33 nm, respectively. The high pore size 
allowed for FBP molecules to be loaded but the low surface 
area was the reason behind low loading percent.
Release profile
The release profiles of FBP@MOFs were evaluated in 
50 mmol PBS at pH 7.4 as a serum fluid (Figure 5). The 
release profile demonstrated two stages for FBP-MOFs. 
In the first stage, the release rates for FBP@Ca-MOF, FBP@
Fe-MIL-101, and FBP@Fe-MIL-100 were around 50% 
within first 2 h, while the release rate for FBP@Fe-MIL-53 
was around 65%. The second stage of FBP release from 
Table 1 Textural properties of MOFs and loading percent of FBP
MOF 
characteristics
Ca-MOF Fe-MIL-53 Fe-MIL-100 Fe-MIL-101
loading (%) 10 (±1.0) 20 (±0.8) 46 (±3.1) 37 (±2.3)
surface area (m²/g) 34.72 26.20 1,604.81 715.19
Pore width (nm) 12.33 12.30 3.02 7.33
Pore volume 
(cm3/g)
0.10 0.06 0.67 0.55
Abbreviations: FBP, flurbiprofen; MOF, metal organic framework.
Figure 5 FBP release profiles in 50 mmol phosphate buffer solution at pH 7.4 
and 37°c.
Abbreviations: FBP, flurbiprofen; MOF, metal organic framework.
FBP@Ca-MOF and FBP@Fe-MIL-53 was a slow stage 
where the FBP was released within 6 h and continued at 
stationary level for 3 days. FBP@Fe-MIL-101 exhibited 
the second stage within 24 h, whereas FBP@Fe-MIL-100 
exhibited within 48 h until it reached the stationary level. 
The total amounts of the FBP released were 72.9%, 75.2%, 
78.3%, and 90.3% for Ca-MOF, Fe-MIL-100, Fe-MIL-53, 
and Fe-MIL-101, respectively.
Discussion
This is the first study that employed MOFs as carrier for FBP 
loading. The highest FBP loading capacity with Fe-MIL-100 
was because of its specific surface area (1,604.81 m²/g) 
and large pore volume (0.67 cm3/g). The lowest loading 
capacity with Ca-MOF is correlated to the low surface area 
(34.71 m2/g) and low pore volume (0.10 cm3/g). The average 
pore size of Ca-MOF was the highest among the employed 
MOFs (12.33 nm), which can open the access for FBP mol-
ecules to be encapsulated inside the pores; however, loading 
capacity was limited because of the small BET surface area, 
low pore volume and the ink-bottle pore effect.28
There are no studies or observations reporting Ca-MOF 
as drug delivery systems to demonstrate a comparison with 
these results. Although the surface area of Fe-MIL-53 was 
26.2 m²/g, it had a pore size of 12.3 nm, which is enough 
to host the FBP molecule and achieve around 20% loading 
capacity. Having a creditable surface area, pore size, and 
volume were the reasons behind the relative high loading 
capacity of Fe-MIL-101 as shown in Table 1. Horcajada et al 
found that both Cr-MIL-53 and Fe-MIL-53 solids adsorb 
around 20% (wt) of ibuprofen,29 and that there was 35% 
loading percent of ibuprofen with MIL-100.30 Although the 
FBP molecule, which is employed in this study, is larger 
than ibuprofen molecule, the Fe-MIL-53 loading capac-
ity (20%) was similar to that of Horcajada et als finding, 
while a significant improvement of Fe-MIL-100 loading 
capacity (46%) was found. Pore size and pore volume of the 
MOFs alongside MOFs’ surface area are the main factors that 
determine the manner and the percentage of the FBP loading 
and release with MOFs as shown in Figure S3. Large pore 
sizes enable different pharmaceuticals to be encapsulated.31 
The drugs of poor aqueous solubility have an affinity for 
encapsulating with hydrophobic pores in MOFs such as the 
MIL family.2 Horcajada and co-workers found unprecedented 
amount of adsorbed ibuprofen (~1.4 g/g MIL-101), which 
was due to large surface area (5,510 m2 g−1).16 The result 
of FBP loading capacity with Fe-MIL-101 was different 
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MOF as flurbiprofen delivery system
in comparison to the ibuprofen molecule and due to the dif-
ferences in the surface area and pore size and volume of the 
Fe-MIL-101.
The FBP release from the FBP@MOFs showed two 
stages. This is related to the FBP location within the pores 
of MOFs, pore size, and kind of host–guest interaction. 
When the filled pores with FBP were located close to the 
surface of MOFs, FBP molecules release concerned only the 
weakly bonded molecules. The first stage was a fast stage 
of release (within 2 h), which can be regarded as zero-order 
kinetics because of drug concentration independence. The 
kinetics of FBP release from FBP@MOFs are empirically 
adjusted with regression factors of 0.99, 0.85, 0.77, and 
0.78 for FBP@Fe-MIL-101, FBP@Fe-MIL-100, FBP@
Ca-MOF, and FBP@Fe-MIL-53, respectively, as shown 
in Figure S4. It can be defined to be a burst effect because 
of the porous structure and high solubility of FBP in PBS 
at pH 7.4 relating to ionization due to the acidic nature of 
FBP (pKa 4.6). The second stage of release can be defined 
as an erosion process due to the slow collapse of the MOFs 
in alkaline media. Frameworks collapsing in PBS are due to 
replacement of the carboxylate linkers by phosphate groups 
in the PBS solution and/or formation of iron oxide rendering 
less favourable formation of stable metal carboxylate bonds 
at pH values above the pKa of carboxylic functions (~4−5).32 
Cunha et al found a rapid release of caffeine from MIL-100 
and 53 within 6 h in a medium of PBS at pH 7.4.32 The col-
lapsing or degradation of MOFs in the body will produce 
materials such as iron oxide33 or organic linkers in MOFs.30
The total percent release of FBP@Fe-MIL-100 and 
53 and Ca-MOF did not reach .90%. However, the final 
drug fraction, probably located inside some micropores, 
therefore, needs more time to be completely released as 
a consequence of the pore diameter and cation–anion and 
π–π interactions.
Conclusion
MOFs have maintained their integrity during the loading 
process. The MOFs have a variety of loading capacities. 
Fe-MIL-100 and 101 were the best MOFs as drug delivery 
systems for FBP. The overall release profile was slow for 
FBP to be formulated as a controlled-release drug. The MOFs 
are a promising material for FBP to be a carrier.
Acknowledgments
We acknowledge the School of Pharmacy, Curtin University, 
for providing access to their laboratories and employing dif-
ferent instruments and materials. The authors acknowledge 
the use of Curtin University’s Microscopy and Microanalysis 
facilities, whose instrumentation has been partially funded by 
University, State, and Commonwealth Government.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. 
Angewandte Chemie International Edition. 2007;46(40):7548–7558.
 2. Huxford RC, Della Rocca J, Lin W. Metal–organic frameworks as poten-
tial drug carriers. Current Opinion in Chemical Biology. 2010;14(2): 
262–268.
 3. Rosi NL, Eddaoudi M, Kim J, O’Keeffe M, Yaghi OM. Advances in the 
chemistry of metal-organic frameworks. Cryst Eng Comm. 2002;4(68): 
401–404.
 4. Meek ST, Greathouse JA, Allendorf MD. Metal-organic frameworks: 
a rapidly growing class of versatile nanoporous materials. Adv Mater. 
2011;23(2):249–267.
 5. Valtchev V, Tosheva L. Porous nanosized particles: preparation, prop-
erties, and applications. Chemical Reviews. 2013;113(8):6734–6760.
 6. Liu R, Li D, He B, et al. Anti-tumor drug delivery of pH-sensitive 
poly(ethylene glycol)-poly(L-histidine-)-poly(L-lactide) nanoparticles. 
Journal of Controlled Release. 2011;152(1):49–56.
 7. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. 
Nanomedicine – challenge and perspectives. Angewandte Chemie 
International Edition. 2009;48(5):872–897.
 8. Zhang J, Wang L-Q, Wang H, Tu K. Micellization phenomena of 
amphiphilic block copolymers based on methoxy poly (ethylene glycol) 
and either crystalline or amorphous poly (caprolactone-b-lactide). 
Biomacromolecules. 2006;7(9):2492–2500.
 9. Cheng Y, Wang J, Rao T, He X, Xu T. Pharmaceutical applications 
of dendrimers: promising nanocarriers for drug delivery. Frontiers in 
Bioscience: a Journal and Virtual Library. 2007;13:1447–1471.
 10. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. 
Int J Pharm. 2004;282(1–2):1–18.
 11. Sun C-Y, Qin C, Wang X-L, Su Z-M. Metal-organic frameworks as 
potential drug delivery systems. Expert Opinion on Drug Delivery. 2013; 
10(1):89–101.
 12. Hinks NJ, McKinlay AC, Xiao B, Wheatley PS, Morris RE. Metal 
organic frameworks as NO delivery materials for biological appli-
cations. Microporous and Mesoporous Materials. 2010;129(3): 
330–334.
 13. Keskin S, Kızılel S. Biomedical applications of metal organic frame-
works. Industrial & Engineering Chemistry Research. 2011;50(4): 
1799–1812.
 14. Férey G. Hybrid porous solids: past, present, future. Chemical Society 
Reviews. 2008;37(1):191–214.
 15. Mizutani M, Maejima N, Jitsukawa K, Masuda H, Einaga H. An infinite 
chiral single-helical structure formed in Cu (II)-L-/D-glutamic acid 
system. Inorganica Chimica Acta. 1998;283(1):105–110.
 16. Horcajada P, Serre C, Vallet-Regí M, Sebban M, Taulelle F, Férey G. 
Metal–organic frameworks as efficient materials for drug delivery. 
Angewandte chemie. 2006;118(36):6120–6124.
 17. Horcajada P, Chalati T, Serre C, et al. Porous metal-organic-framework 
nanoscale carriers as a potential platform for drug delivery and imaging. 
Nature Materials. 2010;9(2):172–178.
 18. Bernini MC, Fairen-Jimenez D, Pasinetti M, Ramirez-Pastor AJ, Snurr RQ. 
Screening of bio-compatible metal–organic frameworks as potential 
drug carriers using Monte Carlo simulations. Journal of Materials 
Chemistry B. 2014;2(7):766–774.
 19. Horcajada P, Chalati T, Serre C, et al. Porous metal-organic-framework 







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




al haydar et al
 20. Chalati T, Horcajada P, Couvreur P, et al. Porous metal organic 
framework nanoparticles to address the challenges related to busulfan 
encapsulation. Nanomedicine. 2011;6(10):1683–1695.
 21. Sumida K, Hu M, Furukawa S, Kitagawa S. Structuralization of 
Ca2+-Based Metal–Organic Frameworks Prepared via Coordination 
Replication of Calcium Carbonate. Inorganic Chemistry. 2016;55(7): 
3700–3705.
 22. Anderson B, Conradi R. Predictive relationships in the water solu-
bility of salts of a nonsteroidal anti-inflammatory drug. Journal of 
Pharmaceutical Sciences. 1985;74(8):815–820.
 23. Begum M, Sudhakar M, Abbulu K. Flurbiprofen-loaded stealth lipo-
somes: studies on the development, characterization, pharmacokinet-
ics, and biodistribution. Journal of Young Pharmacists. 2012;4(4): 
209–219.
 24. Mokhtar M, Sammour OA, Hammad MA, Megrab NA. Effect of some 
formulation parameters on flurbiprofen encapsulation and release rates 
of niosomes prepared from proniosomes. International Journal of 
Pharmaceutics. 2008;361(1):104–111.
 25. Bezverkhyy I, Popova E, Geoffroy N, Herbst F, Bellat J-P. Preparation 
of magnetic composites of MIL-53 (Fe) or MIL-100 (Fe) via partial 
transformation of their framework into γ-Fe 2 O 3. Journal of Materials 
Chemistry A. 2016;4(21):8141–8148.
 26. Maksimchuk NV, Kovalenko KA, Fedin VP, Kholdeeva OA. Cyclo-
hexane selective oxidation over metal–organic frameworks of MIL-101 
family: superior catalytic activity and selectivity. Chemical Communi-
cations. 2012;48(54):6812–6814.
 27. Jiang J, Yaghi OM. Brønsted acidity in metal–organic frameworks. 
Chemical Reviews. 2015;115(14):6966–6997.
 28. Thommes M, Cychosz KA. Physical adsorption characterization of 
nanoporous materials: progress and challenges. Adsorption. 2014;2(20): 
233–250.
 29. Horcajada P, Serre C, Maurin G, et al. Flexible porous metal-organic 
frameworks for a controlled drug delivery. J Am Chem Soc. 2008;130(21): 
6774–6780.
 30. Horcajada P, Gref R, Baati T, et al. Metal–organic frameworks in 
biomedicine. Chemical Reviews. 2011;112(2):1232–1268.
 31. Morris RE, Wheatley PS. Gas storage in nanoporous materials. 
Angewandte Chemie International Edition. 2008;47(27):4966–4981.
 32. Cunha D, Ben Yahia M, Hall S, et al. Rationale of drug encapsulation 
and release from biocompatible porous metal–organic frameworks. 
Chemistry of Materials. 2013;25(14):2767–2776.
 33. Naqvi S, Samim M, Abdin M, et al. Concentration-dependent toxicity 
of iron oxide nanoparticles mediated by increased oxidative stress. 






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




MOF as flurbiprofen delivery system
Supplementary materials
nMr spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy is 
extremely helpful in investigating the interactions between 
the framework and adsorbed species. Solid-state NMR exper-
iments were performed on pure metal organic frameworks 
(MOFs), loaded MOFs, and pure flurbiprofen (FBP). Com-
pared to the spectrum of pure drug, loaded MOFs show the 
resonance of methyl group of FBP molecule to be assigned 




 adsorption–desorption isotherms were obtained and ana-
lyzed to determine the surface area, pore size, and pore volume 
of each MOF separately. Based on the N
2
 adsorption isotherms, 
the Brunauer–Emmett–Teller surface area of all MOFs was 
assessed. The pore volume obtained from the desorption 
isotherm at P/Po 0.99 (Figure S2A–D) and the pore-size dis-
tributions derived from the N
2
 isotherms by the Barrett-Joyner-
Halenda method gave the average pore size of all MOFs.
The FBP release profiles
The release profiles of FBP@MOFs demonstrated two stages. 
The first stage represented by fast release profile and exhibited 
within 2 h. The kinetics of FBP release from FBP@MOFs 
are empirically adjusted with regression factors of 0.99, 
0.85, 0.77, and 0.78 for FBP@MIL-101, FBP@MIL-100, 
FBP@Ca-MOF, and FBP@MIL-53, respectively, as shown 
in Figure S3. These regression factors indicate zero-order 
kinetics behavior.
Figure S1 nuclear magnetic resonance spectrum of ca-MOF (A), Fe-Mil-101 (B), Fe-Mil-53 (C), and Fe-Mil-100 (D).
Abbreviations: FBP, flurbiprofen; MOF, metal organic framework.
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Figure S2 n2 adsorption–desorption behavior of Ca-MOF (A), Fe-Mil-53 (B), Fe-Mil-100 (C), and Fe-Mil-101 (D).
Abbreviation: MOF, metal organic framework.
Figure S3 Relationship of pore size and volume of MOFs with the flurbiprofen loading and release percentages.
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MOF as flurbiprofen delivery system
Figure S4 Kinetic order of first stage of FBP release profiles (∆ FBP@Fe-Mil-53, ◊ FBP@ca-MOF,  FBP@Fe-Mil-100 and X FBP@Fe-Mil-101).
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